BMS and Jiangsu Hengrui Sign 15.2 Billion Dollar Agreement
Jiangsu Hengrui and Bristol Myers Squibb signed deals worth up to 15.2 billion dollars. The 13 early-stage programs focus on cancer and immunology treatments.
Xurve View
Insights:
Xurve View
Jiangsu Hengrui Pharmaceuticals and Bristol Myers Squibb Co signed licensing deals worth up to $15.2 billion in potential milestone payments. The agreement covers 13 early-stage drug programs across oncology, immunology, and blood diseases in China and the United States. Jiangsu Hengrui and Bristol Myers Squibb will exchange global and regional rights to early-stage pharmaceutical assets.
